Kalindi T Parmar

US Patent:

20090136521, May 28, 2009

Filed:

Sep 29, 2006

Appl. No.:

11/992898

Inventors:

Kalindi Parmar - Arlington MA, US
Peter Mauch - Boston MA, US
Julian Down - Cambridge MA, US

Assignee:

Genetix Pharmaceuticals , Inc. - Cambridge MA
Dana-Farber Cancer Institute , Inc. - Boston MA

International Classification:

A61K 39/395
A61K 35/12
A61K 31/53

US Classification:

4241731, 424 937, 424529, 514243

Abstract:

An improved method for selectively depleting hypoxic cells within the bone marrow is disclosed. The method can be used to enhance engraftment of hematopoietic stem cells (HSCs) in the bone marrow of a host subject. Also disclosed is a method for treating a cancer within the bone marrow of a host subject.

US Patent:

20180071330, Mar 15, 2018

Filed:

Feb 26, 2016

Appl. No.:

15/553905

Inventors:

- Boston MA, US
Kalindi PARMAR - Arlington MA, US
Haojian ZHANG - Shrewsbury MA, US

International Classification:

A61K 31/7088
A61K 45/06
C12N 15/113

Abstract:

The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients.

US Patent:

20180051075, Feb 22, 2018

Filed:

Feb 25, 2016

Appl. No.:

15/553930

Inventors:

- Boston MA, US
Kalindi PARMAR - Arlington MA, US
Haojian ZHANG - Shrewsbury MA, US

International Classification:

C07K 16/22

Abstract:

The present invention provides methods of treating, preventing or delaying the onset of bone marrow failure in Fanconi Anemia patients comprising administering to the patient a composition comprising a neutralizing anti-TGF-beta antibody, e.g. fresolimumab or 1D11.